Researchers at Weill Cornell Medicine are advancing tuberculosis (TB) vaccines by incorporating engineered mycobacteria strains with ‘kill switches.’ These innovative mechanisms can deactivate bacteria after triggering an immune response, potentially improving the safety of controlled human infection trials and enhancing vaccine efficacy.
About the Author
